Schizophrenia: Prevention and treatment of atypical antipsychotic drug-induced obesity

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/635231

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Atypical antipsychotic drugs such as olanzapine, clozapine and risperidone are commonly used to treat mental illness. While these drugs are effective, their side effects of obesity and metabolic disorders are a major hurdle leading to a serious lack of compliance in taking medication. This project will define the mechanism leading to these side effects and will help to identify pharmaceutical targets for the better treatment of mentally ill patients.

Funded Activity Details

Start Date: 01-01-2010

End Date: 01-01-2013

Funding Scheme: NHMRC Project Grants

Funding Amount: $413,862.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Psychiatry (incl. Psychotherapy)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Antipsychotic | Antipsychotic Treatment | Energy Balance | Neuropeptide Y | Obesity | Schizophrenia

Related Links